The T cell landscape with the information of paired TCR α and β chains in liver cancers comprehensively discloses the transition route of exhausted CD8+ T cells in HCC and highlights that a subset of CD8+ T cells with intermediate levels of PDCD1 and TIGIT can be the target cells for immunotherapies (106). This evidence concerns the gene CD8A and liver cancer.